Acumen Pharmaceuticals, Inc.(ABOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABOS Acumen Pharmaceuticals, Inc.

Market Closed 12-19 16:00:00 EST

2.15

+0.03

+1.42%

盘后2.11

-0.04-1.86%

18:30 EST

High2.28	Low2.11	Vol263.39K
Open2.11	D1 Closing2.12	Amplitude8.05%
Mkt Cap130.23M	Tradable Cap70.80M	Total Shares60.57M
T/O577.41K	T/O Rate0.80%	Tradable Shares32.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABOS","market":"US","secType":"STK","nameCN":"Acumen Pharmaceuticals, Inc.","latestPrice":2.15,"timestamp":1766178000000,"preClose":2.12,"halted":0,"volume":263389,"hourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.15,"latestTime":"18:30 EST","volume":671,"amount":1417.2,"timestamp":1766187017789},"delay":0,"floatShares":32929494,"shares":60573425,"eps":-2.206395,"marketStatus":"Market Closed","change":0.03,"latestTime":"12-19 16:00:00 EST","open":2.11,"high":2.28,"low":2.1093,"amount":577413.5870496001,"amplitude":0.080519,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.206395,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"listingDate":1625112000000,"exchange":"NASDAQ","adjPreClose":2.12,"preHourTrading":{"tag":"盘前","latestPrice":2.08,"preClose":2.12,"latestTime":"08:38 EST","volume":592,"amount":1231.0898112,"timestamp":1766151510786},"postHourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.15,"latestTime":"18:30 EST","volume":671,"amount":1417.2,"timestamp":1766187017789},"volumeRatio":1.5530814569930789,"impliedVol":0.7887,"impliedVolPercentile":0.352},"requestUrl":"/m/hq/s/ABOS/tweets","defaultTab":"tweets","newsList":[{"id":"2588340059","title":"BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2588340059","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588340059?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:13","pubTimestamp":1764684837,"startTime":"0","endTime":"0","summary":"BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies Dec 2 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O:ACUMEN PHARMACEUTICALS HIGHLIGHTS ENHAN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA3PZWFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2588534700","title":"Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588534700","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588534700?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680442,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease  conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug , to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer's disease studies. The results were presented at the conference, and data posters are available on the company's website.Disclaimer: This news brief was created by Public Technol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL9y0Z90:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","BK4588","BK4539","LU0314104364.USD","ABOS","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","NDAQ","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2588305390","title":"Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 Altitude-Ad Clinical Trial at 18TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588305390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588305390?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA3PZWFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","ABOS","BK4139"],"gpt_icon":0},{"id":"2584957995","title":"Acumen Pharmaceuticals Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957995","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584957995?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:08","pubTimestamp":1763489280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 13:08 ET (18:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0},{"id":"2584795859","title":"Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584795859","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584795859?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:00","pubTimestamp":1763470800,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., Nov.  18, 2025  (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3189967/0/en/Acumen-Pharmaceuticals-to-Present-on-Recruitment-Strategies-for-Phase-2-ALTITUDE-AD-Trial-and-Enhanced-Brain-Delivery-Technology-at-18th-Annual-Clinical-Trials-on-Alzheimer-s-Disea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BBB","BK4139","BK4135","BK4132","AD","ABOS","BK4539"],"gpt_icon":0},{"id":"2584625844","title":"Acumen Pharmaceuticals Doses First Participant in Phase 2 Extension Study of Sabirnetug for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625844","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625844?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384457,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc. has announced the dosing of the first participant in the open-label extension  phase of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug  in individuals with early Alzheimer's disease. This extension allows participants who completed the initial 18-month placebo-controlled portion to receive sabirnetug at 35 mg/kg intravenously every four weeks for an additional 52 weeks. The study will continue to monitor clinical measures and safety. Sabirnetug is a humanized monoclonal antibody targeting soluble amyloid beta oligomers. Topline results from the ALTITUDE-AD trial are expected to be reported in late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the ori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7vtLPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4588","BK4139","BK4112","ABOS","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","BK4539"],"gpt_icon":0},{"id":"2584625358","title":"Acumen Pharmaceuticals Inc: Acumen Expects to Report Topline Results From Altitude-Ad in Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625358?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA7X5R09:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2584331625","title":"Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2584331625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584331625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA7X5R09:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","ABOS","BK4139"],"gpt_icon":0},{"id":"2583598323","title":"Acumen Pharmaceuticals Inc - May Offer Common Stock up to $50 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598323?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:06","pubTimestamp":1763039192,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1UO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2583569021","title":"Citi Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569021?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:17","pubTimestamp":1763032658,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on Acumen Pharmaceuticals, with a price target of $4.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-its-buy-rating-for-acumen-pharmaceuticals-abos-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-its-buy-rating-for-acumen-pharmaceuticals-abos-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABOS"],"gpt_icon":0},{"id":"2583587766","title":"Acumen Pharmaceuticals’ Earnings Call: Progress and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2583587766","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583587766?lang=en_us&edition=fundamental","pubTime":"2025-11-13 08:30","pubTimestamp":1762993830,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals, Inc. (($ABOS)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Acu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acumen-pharmaceuticals-earnings-call-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acumen-pharmaceuticals-earnings-call-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABOS","PRGS"],"gpt_icon":0},{"id":"2582376069","title":"Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376069","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376069?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:48","pubTimestamp":1762951689,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease . The company highlighted sabirnetug , a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery  program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7ZRP6v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABOS","BK4539"],"gpt_icon":0},{"id":"2582376175","title":"Acumen Pharmaceuticals Reports Q3 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376175","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376175?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:33","pubTimestamp":1762950813,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals ( ($ABOS) ) has provided an announcement. On November 12, 2025, Acumen Pharmaceuticals reported its third-quarter financial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acumen-pharmaceuticals-reports-q3-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acumen-pharmaceuticals-reports-q3-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2582375553","title":"Biopharma firm Acumen's Q3 net loss narrows, beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375553","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375553?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:07","pubTimestamp":1762949263,"startTime":"0","endTime":"0","summary":"Biopharma firm Acumen's Q3 net loss narrows, beats estimatesOverviewAcumen Q3 net income and income from operations beat analyst estimatesCompany's cash expected to support operations into early 2027R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS","BK4539","BK4139"],"gpt_icon":0},{"id":"2582373963","title":"BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -26.513 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373963","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373963?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948848,"startTime":"0","endTime":"0","summary":"BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -26.513 Million\n\n\nNov 12 (Reuters) - Acumen Pharmaceuticals, Inc. Q3 net income USD -26.451 million.\n\nQ3 basic EPS USD -0.44\nQ3 operating expenses USD 26.513 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX6310DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2582373179","title":"Acumen Pharmaceuticals Q3 EPS $(0.44) Beats $(0.58) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373179","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373179?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948840,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Q3 EPS $(0.44) Beats $(0.58) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48798690/acumen-pharmaceuticals-q3-eps-0-44-beats-0-58-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS"],"gpt_icon":0},{"id":"2582739273","title":"Acumen Pharmaceuticals posts Q3 2025 cash balance of $136.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582739273","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582739273?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948837,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals Inc. reported a net loss of $26.5 million for the third quarter of 2025, compared to a net loss of $29.8 million for the same period in 2024. Cash, cash equivalents, and marketable securities totaled $136.1 million as of September 30, 2025, down from $166.2 million as of June 30, 2025. The company expects its cash position to support current clinical and operational activities into early 2027. Key business developments include the anticipated decision on advancing an amyloid beta oligomer-targeted Enhanced Brain Delivery product candidate in early 2026, and expected topline results from the Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLb8bVH8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4539","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","ABOS","NDAQ","LU2210149790.SGD","BK4585","BK4112","BK4139"],"gpt_icon":0},{"id":"2582949375","title":"Acumen Pharmaceuticals Inc: Expects Non-Clinical Data to Support Development of Ebd Therapy in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582949375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582949375?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX6310DB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","ABOS"],"gpt_icon":0},{"id":"2582373664","title":"Acumen Pharmaceuticals, Inc. Q3 Basic EPS USD -0.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373664?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX6310DB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABOS","BK4539"],"gpt_icon":0},{"id":"2582337327","title":"Press Release: Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582337327","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582337327?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"-- Expect decision regarding the advancement of an A<BETA> oligomer-targeted. Enhanced Brain DeliveryTM product candidate in early 2026. -- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to. investigate sabirnetug  for the treatment of early Alzheimer's. -- Cash, cash equivalents and marketable securities of $136.1 million as of. Sept. 30, 2025, expected to support current clinical and operational. \"We continued our strong operational progress throughout the third quarter, both clinically, with our ongoing Phase 2 trial of sabirnetug, and non-clinically, with the advancement of our Enhanced Brain Delivery  program. Our goal remains clear: to deliver meaningful innovation for patients,\" said Daniel O'Connell, Chief Executive Officer of Acumen. \"We remain focused on translating cutting-edge science into novel medicines with the greatest potential to benefit patients, while deploying capital with the goal of maximizing shareholder value. We anticipate non-clinical data ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4604","BK4099","BK4022","ABOS","BK4232","BK4539","TM","BK4588","03160","AD","BK4585","BK4555","BK4187","BETA","R","BK4132"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acumenpharm.com","stockEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.3871},{"period":"3month","weight":0.7063},{"period":"6month","weight":0.7917},{"period":"1year","weight":0.1944},{"period":"ytd","weight":0.25}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.08143},{"month":2,"riseRate":0.5,"avgChangeRate":0.038835},{"month":3,"riseRate":0,"avgChangeRate":-0.190829},{"month":4,"riseRate":0.25,"avgChangeRate":-0.059929},{"month":5,"riseRate":0.25,"avgChangeRate":0.002499},{"month":6,"riseRate":0.5,"avgChangeRate":0.065932},{"month":7,"riseRate":1,"avgChangeRate":0.316611},{"month":8,"riseRate":0.4,"avgChangeRate":-0.036235},{"month":9,"riseRate":0.4,"avgChangeRate":0.088763},{"month":10,"riseRate":0.4,"avgChangeRate":-0.092058},{"month":11,"riseRate":0.2,"avgChangeRate":-0.138923},{"month":12,"riseRate":0.4,"avgChangeRate":0.061545}],"exchange":"NASDAQ","name":"Acumen Pharmaceuticals, Inc.","nameEN":"Acumen Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acumen Pharmaceuticals, Inc.(ABOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acumen Pharmaceuticals, Inc.(ABOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acumen Pharmaceuticals, Inc.,ABOS,Acumen Pharmaceuticals, Inc.股票,Acumen Pharmaceuticals, Inc.股票老虎,Acumen Pharmaceuticals, Inc.股票老虎国际,Acumen Pharmaceuticals, Inc.行情,Acumen Pharmaceuticals, Inc.股票行情,Acumen Pharmaceuticals, Inc.股价,Acumen Pharmaceuticals, Inc.股市,Acumen Pharmaceuticals, Inc.股票价格,Acumen Pharmaceuticals, Inc.股票交易,Acumen Pharmaceuticals, Inc.股票购买,Acumen Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acumen Pharmaceuticals, Inc.(ABOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acumen Pharmaceuticals, Inc.(ABOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}